ArticleJournal of dentistry (Shiraz, Iran)2025
Immunohistochemical Expression of Baculoviral Inhibitor of Apoptotic Proteins Repeat-Containing Protein in Tumors of Salivary Gland Origin.
Article in Journal of dentistry (Shiraz, Iran), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Salivary gland tumors (SGTs) include benign and malignant tumors, such as pleomorphic adenoma (PA), mucoepidermoid carcinoma (MEC), and adenoid cystic carcinoma (ACC). Baculoviral inhibitors of apoptotic proteins (BIAPs) repeat-containing protein 6 (BIRC6), is an anti-apoptotic protein that plays an important role in cancers. Purpose: We aimed to evaluate the expression of BIRC6 in SGTs and its correlation with the clinicopathological features. Materials and Method: In this cross-sectional study, 56 SGT tissue samples, including 15 cases of MEC, 20 cases of ACC, and 21 cases of PA, as well as nine cases of normal salivary gland tissues, were investigated for BIRC6 expression by immunohistochemical analysis. Results: BIRC6 was found in 2.50%, 63%, 88%, and 63% of normal tissue, MEC, ACC, and PA, respectively. The mean total score of BIRC6 expression was 9.13; for ACC, MEC, PA, and normal tissue of the salivary gland were 10.25, 9.13, 9.00, and 3.00, respectively. The high expression of BIRC6 was detected in 29 cases of malignant and 15 cases of benign SGTs. The frequency of high or low expression was not different between the male and female patients ( Conclusion: The higher expression intensity and percentage of BIRC6 in malignant and benign SGTs suggests it as a potential marker to be used in future targeted therapy for SGTs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.